Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

NCT03457818 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped Due to enrollment difficulties compounded by the COVID pandemic.

Conditions

Diabetes Mellitus, Type 2
Osteoporosis

Interventions

DRUG: Denosumab 60 mg/ml [Prolia]
OTHER: Placebo

Sponsor

Mishaela Rubin